Nanjing Medlander Medical Technology Co.,Ltd. (SHSE:688273) signed the Equity Transfer Agreement to acquire 55% stake in Nanjing Maidou Health Technology Co., Ltd. from Wu Henglong, Zheng Weifeng, Nanjing Xinlan Equity Investment Partnership (Limited Partnership) and Nanjing Maichuang Enterprise Management Partnership Enterprise (Limited Partnership) for approximately CNY 190 million on May 22, 2024. The consideration consists of CNY 192.5 million in cash. As part of the consideration, CNY 192.5 million was paid towards common equity. Nanjing Medlander Medical Technology Co.,Ltd. will fund the acquisition from it's own resources. As of March 31, 2024, Nanjing Maidou Health Technology Co., Ltd. reported total assets of CNY 41.6 billion million and net assets of CNY 28.4 million. The deal has been approved by board of directors of Nanjing Medlander Medical Technology.

Nanjing Medlander Medical Technology Co.,Ltd. (SHSE:688273) cancelled the acquisition of 55% stake in Nanjing Maidou Health Technology Co., Ltd. from Wu Henglong, Zheng Weifeng, Nanjing Xinlan Equity Investment Partnership (Limited Partnership) and Nanjing Maichuang Enterprise Management Partnership Enterprise (Limited Partnership) on May 30, 2024.